Bachem heading for OPT 2022 Congress in Boston

Bubendorf, Switzerland: – Peptide technology specialist Bachem AG will be a prominent participant in the return of America’s Oligonucleotide & Precision Therapeutics (OPT) Congress as a live event in mid-March 2022.

Bachem Americas, based in Torrance CA, will be a corporate sponsor of the 7^th OPT Congress and will also contribute a presentation to the Oligonucleotides CMC and Regulatory program.

Bachem oligonucleotide cGMP manufacturing 

During the CMC & Regulatory Insights session on the morning of Day Two (March 16),  Joseph Fraone, Business Development Manager for Oligonucleotides at Bachem Americas, Inc. will speak on ‘Turning Tides Together: Oligonucleotide Manufacturing at Bachem’.

The presentation (1000-1015 hrs.) will highlight’s Bachem’s expansion from a leading international CMO for pharmaceutical grade peptides to become the first CMO servicing the global ‘Tides market

Expanding oligonucleotide NCE expertise

Bachem Americas will also send a team to staff its exhibition stand at Booth 12 in the Revere Hotel’s Bohea Ballroom. Their displays will highlight Bachem’s recent expansion of its CMO technology platforms to offer chemical manufacturing services for nucleic acid based APIs including Oligonucleotide-based new chemical entities (NCEs).

The stand will also present Bachem’s capacity and technology advances in oligo synthesis.

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. With over 50 years of experience and expertise, Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.

Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.

About OPT Congress 2022

The annual Oligonucleotide & Precision Therapeutics (OPT) Congress provides a unique opportunity to discuss advances in next-generation oligonucleotide therapies throughout the drug development process.

The event brings together leading discovery and development scientists, CMC and regulatory experts, and technology providers, with a focus on optimizing drug design and delivery, streamlining manufacturing and regulatory issues and accelerating time to market.

Making its return as a physical face-to-face event after moving online in 2020 and 2021 due to the Covid-19 pandemic,  the 7th Annual OPT 2022 Congress will be a two day event opening March 15 at the Revere Hotel Boston Common in Boston, MA.

Organisers have instituted mandatory health and safety protocols for all in-person participants, including prior proof of full vaccination against COVID-19 and negative FDA-authorized test results.

The theme of the 2022 Congress will concern ‘Discovery and Delivery: Optimizing Design, Delivery and Performance’ with a continuation of the Oligonucleotide CMC & Regulatory Strategies program focusing on oligonucleotide discovery and delivery.

The event is organized by the Massachusetts-based Cambridge Healthtech Institute with further information at: https://www.optcongress.com

Resources

Click on Bachem Oligonucleotide New Chemical Entities NCEs for more information.
Click on Bachem at OPT Congress 2022 for further information.
Click on Bachems News to see latest News & Events.